{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:19:51Z","timestamp":1790273991394,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.toxlet.2014.10.026","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T22:07:06Z","timestamp":1414188426000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Contribution of human esterases to the metabolism of selected drugs of abuse"],"prefix":"10.1016","volume":"232","author":[{"given":"Markus R.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans H.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2014.10.026_bib0005","first-page":"1089","article-title":"Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs","volume":"25","author":"Brzezinski","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0010","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1111\/j.1476-5381.2010.00700.x","article-title":"Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin","volume":"160","author":"Hatfield","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2133\/dmpk.21.173","article-title":"Human carboxylesterase isozymes: catalytic properties and rational drug design","volume":"21","author":"Imai","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0020","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.106.009381","article-title":"Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine","volume":"34","author":"Imai","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0022-3565(25)21180-6","article-title":"Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases","volume":"279","author":"Kamendulis","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/dta.362","article-title":"The syntheses and characterization 3beta-(4-fluorobenzoyloxy) tropane (fluorotropacocaine) and its 3alpha isomer","volume":"4","author":"Kavanagh","year":"2012","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/phar.1194","article-title":"The role of human carboxylesterases in drug metabolism: have we overlooked their importance?","volume":"33","author":"Laizure","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.toxlet.2014.10.026_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.113.054353","article-title":"Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis","volume":"42","author":"Laizure","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0045","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.bcp.2005.09.002","article-title":"Butyrylcholinesterase, paraoxonase, and albumin esterase but not carboxylesterase, are present in human plasma","volume":"70","author":"Li","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygeno.2004.07.008","article-title":"Pharmacogenomic assessment of carboxylesterases 1 and 2","volume":"84","author":"Marsh","year":"2004","journal-title":"Genomics"},{"key":"10.1016\/j.toxlet.2014.10.026_bib0055","series-title":"Maurer\/Wissenbach\/Weber MWW LC-MSn Library of Drugs, Poisons, and their Metabolites","author":"Maurer","year":"2014"},{"key":"10.1016\/j.toxlet.2014.10.026_bib0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00216-013-7425-9","article-title":"A qualitative\/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 beta-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches","volume":"406","author":"Meyer","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0065","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/sj.clpt.6100082","article-title":"Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics","volume":"81","author":"Patrick","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0070","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jms.1607","article-title":"Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry","volume":"44","author":"Philipp","year":"2009","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0075","doi-asserted-by":"crossref","first-page":"14769","DOI":"10.1074\/jbc.272.23.14769","article-title":"Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin","volume":"272","author":"Pindel","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0080","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1124\/jpet.104.081265","article-title":"Hydrolysis of capecitabine to 5\u2032-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide","volume":"313","author":"Quinney","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0085","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1042\/bst0310620","article-title":"Human carboxylesterase 1: from drug metabolism to drug discovery","volume":"31","author":"Redinbo","year":"2003","journal-title":"Biochem. Soc. Trans."},{"issue":"7","key":"10.1016\/j.toxlet.2014.10.026_bib0090","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1124\/dmd.114.056994","article-title":"Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase","volume":"42","author":"Shimizu","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.104.067116","article-title":"Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1","volume":"310","author":"Sun","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/dmd.113.053512","article-title":"In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors","volume":"42","author":"Thomsen","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0105","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1124\/dmd.111.039628","article-title":"Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2","volume":"39","author":"Wang","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0110","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s00216-011-5032-1","article-title":"Drugs of abuse screening in urine as part of a metabolite-based LC\u2013MS(n) screening concept","volume":"400","author":"Wissenbach","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.toxlet.2014.10.026_bib0115","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chroma.2007.02.024","article-title":"Characterization of procaine metabolism as probe for the butyrylcholinesterase enzyme investigation by simultaneous determination of procaine and its metabolite using capillary electrophoresis with electrochemiluminescence detection","volume":"1154","author":"Yuan","year":"2007","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.toxlet.2014.10.026_bib0120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tox.2010.01.009","article-title":"Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions","volume":"270","author":"Zhu","year":"2010","journal-title":"Toxicology"},{"key":"10.1016\/j.toxlet.2014.10.026_bib0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jchromb.2011.02.033","article-title":"Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography\u2013tandem mass spectrometry: application to human ethanol interactions","volume":"879","author":"Zhu","year":"2011","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427414014088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427414014088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T13:21:12Z","timestamp":1746451272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427414014088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0378427414014088"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2014.10.026","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of human esterases to the metabolism of selected drugs of abuse","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2014.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}